Samumed Continues to Pour Funding into Wnt Pathway Therapies

Samumed is noteworthy for the breadth of their regenerative medicine development pipeline, based as it is on a single technology platform, the manipulation of Wnt signaling. Their trials to date are attempts to use variations on this approach to increase regenerative capacity in aging and damaged tissues. The company might be viewed as an early example of the fork in the road for the regenerative medicine community, arising after first generation stem cell therapies have matured. Some groups will produce better, more advanced cell therapies, aiming to improve the survival and utility of transplanted cells. Others, like Samumed, will abandon cell transplants in favor of ways to manipulate native cell populations to produce similar outcomes. At least a few of the future successful companies in the rejuvenation research space should come to look quite similar to Samumed in structure. Most legitimate rejuvenation therapies, those capable of at least partially reversing one of the root causes of aging, will be applicable to scores of age-related diseases. Companies will be limited in size and activity only by the amount of funding they can raise. It will not be unusual to see the likes of Samumed or Unity Biotechnology raising hundreds of millions of dollars for very broad pipelines, with trials of their technology for a dozen or more age-related conditions running in parallel. Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs